**ISPOR Russia St. Petersburg Chapter**

**Annual Report 2018**

To: Board of Directors

International Society for Pharmacoeconomics and Outcomes Research

505 Lawrence Square Boulevard

South Lawrenceville, ТО 08648 USA

**PREPARED BY**

Professor Alexey S. Kolbin, MD, PhD, Doctor of Science, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University;

Yulia E. Balykina, PhD, associate professor, St Petersburg State University, faculty of Applied Mathematics and Control Processes.

**President of ISPOR Russia St. Petersburg Regional Chapter**

Alexey S. Kolbin, MD, PhD, Doctor of Science, Professor, Head of the Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University; Professor at the Medical Faculty of St. Petersburg State University, St. Petersburg, Russia

**President-Elect**

Sergey K. Zyryanov, MD, PhD, Professor, Head of the Department of Clinical Pharmacology of the RUDN University, Moscow, Russia

**Director**

Dmitry Yu. Belousov, Science Editor “Good clinical practice”, Moscow, Russia

**Secretary**

Alexey A. Kurylev, MD, Department of clinical pharmacology and evidence-based medicine, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.

For more information on the Chapter, please visit at ***https://www.ispor.org/member-groups/global-groups/regional-chapters/russia-st-petersburg***

**Activities of the Chapter in 2018:**

**I. Publications in the Field of Pharmacoeconomics and Health Technology Assessment**

|  |  |  |  |
| --- | --- | --- | --- |
| № | Title | Journal | Authors |
| 1 | Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes, and capecitabine | Modern oncology. 2018;(1):64–69. | Kolbin A.S., Mosikyan A.A., Balykina Y.E., Proskurin M.A. |
| 2 | Clinical trial results and real world medical evidence gap: literature overview. | The Scientific Notes of the I.P. Pavlov St. Petersburg State Medical University. 2018;25(1):7–14. DOI: 10.24884/1607-4181-2018-25-1-7-14 | Philippova A.V., Kolbin A.S. |
| 3 | Simulation of bacterial resistance for different antibiotic consumption strategies based on the *Escherichia coli* resistance to cephalosporins | Clinical Microbiology and Antimicrobial Chemotherapy. 2017;19(4):321–326. | Arepeva M.A., Kolbin A.S., Sidorenko S.V., Kurylev А.А. |
| 4 | Network meta-analysis for Parnaparine effectiveness in venous thromboembolic prevention in surgery | Tromboz, gemostaz i Reologia. 2018;(73):31–38. | Morozov K.M., Kolbin A.S., Galankin T.L. |
| 5 | CYP2D6 genotyping in the daily routine of a psychiatric hospital - pharmacoeconomic evaluation | PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2018;11(1):19–26. DOI: 10.17749/2070-4909.2018.11.1.019-026 | Kurylev A.A., Andreev B.V., Kolbin A.S., Limankin O.V. |
| 6 | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics | PHARMACOECONOMICS. Modern Pharmacoeconomics and Pharmacoepidemiology. 2018;11(1):27–36. DOI: 10.17749/2070-4909.2018.11.1.027-036 | Gomon Yu.M., Arepyeva M.A., Balykina Yu.E., Kolbin A.S., Kurylev A.A., Proskurin M.A., Sidorenko S.V. |
| 7 | Complicated intra-abdominal infection at multidisciplinary hospital: economics of real practice of antimicrobial treatment | Pharmacoeconomics: theory and practice. 2018;1(6):13-23. DOI: https://doi.org/10.30809/phe.1.2018.2 | Gomon Yu.M., Kolbin A.S., Balykina Yu.E., Arepyeva M.A., Sidorenko S.V., Strizheletskiy V.V., Ivanov I.G., Lobzin Yu.V. |
| 8 | Pharmacoeconomic evaluation of mirabegron: results of the healthcare budget impact analysis | Good Clinical Practice. 2018;1:15-24. DOI: 10.24411/2588-0519-2018-10034 | Kolbin A.S., Vilyum I.A., Proskurin M.A., Balykina Yu.E. |
| 9 | Pharmacoeconomic analysis of dexamethasone intravitreal implant for the treatment of diabetic macular edema in Russia | Good Clinical Practice. 2018;1:41-52. DOI: 10.24411/2588-0519-2018-10037 | Kolbin A.S., Galankin T.L., Kaleev A.I. |
| 10 | Socioeconomic burden of atrial fibrillations in Russia: seven-year trends (2010-2017) | Journal of arrhythmology. 2018;92:42-48. DOI: 10.25760/VA-2018-92-42-48 | Kolbin A.S., Mosikyan A.A., Tatarsky B.A. |
| 11 | Optimization Approach for Estimating the Required Amount of Pharmaceuticals in the Russian Federation | Value in Health Regional Issues. 2018;16:39-45. DOI: 10.1016/j.vhri.2018.04.002 | Prasolov, A.V., Kolbin, A.S., Balykina, Y.E. |
| 12 | Analysis of consumption of antibacterial drugs for systemic use in hospitals of Saint Petersburg in 2014–2015 | Journal Infectology. 2018;10(3):115-123. DOI: 10.22625/2072-6732-2018-10-3-115-123 | Gomon Y.M., Kurylev A.A., Kolbin A.S., Proskurin M.A., Ivanov I.G., Sidorenko S.V., Arepieva M.A., Sokolov A.V. |
| 13 | Clinical and economic evaluation of treatment of lysosomal acid lipase deficiency | Clinical Pharmacology and Therapy. 2018;27(4):98-104. | Kolbin A.S., Vilyum I.A., Proskurin M.A., Balykina Yu.E. |
| 14 | What is the role of antineoplastic drug safety in reimbursement decision making? | PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2018;11(3):38-42. DOI: 10.17749/2070-4909.2018.11.3-038-042 | Kolbin A.S., Kurylev A.A. |
| 15 | Cost-benefit analysis of regimens of antibacterial therapy for acute uncomplicated pyelonephritis | Effective pharmacotherapy: urology and nephrology. 2018;3-4 (29):4-16 | Gomon Yu.M., Kolbin A.S., Balykina Yu.E., Arepyeva M.A., Sidorenko S.V., Strizheletsky V.V., Ivanov I.G. |
| 16 | Forecasting economic effect of Alirocumab in patients with hypercholesteremia and high cardiovascular risk | Clinical pharmacology and therapy. 2018;27(1):90-96. | Zyuryanov S.K., Diakov I.N., Karpov O.I. |
| 17 | Pharmacoeconomic study of drugs used in the treatment of moderate and severe psoriasis in patients with ineffective basic systemic therapy | Clinical pharmacology and therapy. 2018;27(4):91-97. | Zyryanov S.K., Cheberda A.E., Belousov D.Yu. |
| 18 | A problem of inhaled drug substitutions: analysis of data from the Russian database on adverse events | Russian Pulmonology. 2018;28(4):424-429. DOI: 10.18093/0869-0189-2018-28-4-424-429 | Zyryanov S.K., Zatolochina K.E., Asetskaya I.L. |
| 19 | Pharmacoeconomic assessment of dual bronchodilation therapy in patients with COPD | Russian Pulmonology. 2018;28(1):61-68. DOI: 10.18093/0869-0189-2018-28-1-61-68 | Zyryanov S.K., D'yakov I.N. |
| 20 | Perspectives for use of the radionuclide drugs in the treatment of malignant tumors in Russia | Good Clinical Practice. 2018;2:51-57. DOI: 10.24411/2588-0519-2018-10044 | Zyryanov S.K., Zatolochina K.E. |
| 21 | Pharmacoeconomic analysis of flexible-dose administration regimen of Xeomine® in patients with focal dystonia | Good Clinical Practice. 2018;(1):53-65. DOI: 10.24411/2588-0519-2018-10038 | Cheberda A.E., Belousov D.Y., Zyryanov S.K. |
| 22 | GCP inspection by Roszdravnadzor | Good Clinical Practice. 2018;(1):66-76. DOI: 10.24411/2588-0519-2018-10039 | Rogov E.S., Belousov D.Y., Zyryanov S.K., Kolbin A.S., Karpenko L.I. |
| 23 | Pharmacoeconomic analysis of chronic heart failure drug therapy in patients with comorbid conditions | Rational Pharmacotherapy in Cardiology. 2018;14(2):167-175. DOI: 10.20996/1819-6446-2018-14-2-167-175 | Zyryanov S.K., Cheberda A.E., Belousov D.Y. |
| 24 | Resolution of the Expert Council “Empirical antibacterial therapy of respiratory infections and the risk factors of resistant flora” | Handbook for Practitioners Doctors. 2018;1:28-32. | Kozlov R.S., Zyryanov S.K., Sinopalnikov A.I., Ryazantsev S.V., Styrt E.A. |
| 25 | Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropium-olodaterol in patients with chronic obstructive pulmonary disease | Medical Council. 2018;6:61-65. DOI: 10.21518/2079-701X-2018-6-61-65 | Zyryanov S.K., Galatonova Y.A. |
| 26 | Pharmacoeconomic Analysis of Afatinib and Gefitinib for the Treatment of Lung Cancer | Medical Technologies. Assessment and Choice. 2018;1(31): 68-84. | Fedyayev D. V., Zyryanov S. K. |
| 27 | Experience of studying the medical and social characteristics of patients receiving chemotherapy in a specialized hospital. | Proceedings of the V All-Russian scientific conference with international participation “Public Health and Quality of Life”, St. Petersburg., 2018. pp. 246-254. | Pavlysh A.V., Vishnyakov N.I. |
| 28 | Clinical and pharmacoeconomic aspects of neoadjuvant therapy of breast cancer | Medical Council. 2018;10:140-145. DOI: 10.21518/2079-701X-2018-10-140-145 | Kostorov V.A., Semiglazova T.Yu., Pavlysh A.V. |
| 29 | Economic losses due to low coverage of lipid-lowering therapy in patients with cardiovascular diseases in the Russian Federation | Rational Pharmacotherapy in Cardiology. 2018;14(5):716-724. DOI: 10.20996/1819-6446-2018-14-5-716-724 | Karpov O.I., Balanova YA., Kontsevaya A.V., Imaeva A.E., Khudyakov M.B. |
| 30 | Economic burden of hypercholesterolemia in the Russian Federation | Rational Pharmacotherapy in Cardiology. 2018;14(3):393-401. DOI: 10.20996/1819-6446-2018-14-3-393-401 | Karpov O.I., Kontsevaya A.V., Balanova YA., Imaeva A.E., Khudyakov M.B., Drapkina O.M. |
| 31 | Vaccine prevention of pneumococcal infection in children | Pediatric pharmacology. 2018;15(3):200-211. DOI: 10.15690/pf.v15i3.1899 | Baranov A.A., Namazova-Baranova L.S., Brico N.I., Lobzin Y.V., Коzlov R.S., Kostinov M.P., Koroleva I.S., Rudakova A.V., Sidorenko S.V., Tatochenko V.K., Kharit S.M., Fedoseenko M.V., Vishneva E.A., Selimzyanova L.R. |
| 32 | Economic feasibility of new chemotherapy regimens for treatment of tuberculosis patients with extensive drug resistance | Tuberculosis and Lung Diseases. 2018;96(6):7-14. DOI: 10.21292/2075-1230-2018-96-6-7-14 | Vasilyeva I.А., Samoylova А.G., Rudakova А.V., Lovacheva O.V., Glebov K.А., Chernousova L.N. |
| 33 | Vaccination against pneumococcal infections in Russian Federation: social and pharmacoeconomic aspects | Journal Infectology. 2018;10(3):11-22. DOI: 10.22625/2072-6732-2018-10-3-11-22 | Rudakova A.V., Briko N.I., Lobzin Y.V., Namazova-Baranova L.S., Avdeev S.N., Ignatova G.L., Kostinov M.P., Koroleva I.S., Polibin R.V., Fomin I.V. |
| 34 | Use of highly concentrated polyunsaturated fatty acids for prevention of complications after myocardial infarction. Cost-Utility analysis | Kardiologiia. 2018;58(2):77–82. DOI: 10.18087/cardio.2018.2.10089 | Plavinskii S.L., Barinova A.N. |
| 35 | Pharmacoeconomic analysis of Cellex® in the treatment of ischemic stroke | Good clinical practice. 2018;(1):25-34. DOI: 10.24411/2588-0519-2018-10035 | Cheberda A.E., Belousov D.Y. |
| 36 | Clinical and economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation | Good clinical practice. 2018;(2):13-28. DOI: 10.24411/2588-0519-2018-10041 | Belousov D.Y., Cheberda A.E., Afanasyeva E.V., Gladkov O.A. |
| 37 | Pharmacoeconomic analysis of different methods for the treatment of steroid-refractory graft-versus-host disease: single-center study | The Scientific Notes of the I. P. Pavlov St. Petersburg State Medical University. 2018;25(1):35-44. DOI: 10.24884/1607-4181-2018-25-1-35-44 | Moiseev I.S., Galankin T.L., Dotsenko A.A., Burmina E.A., Fedukova Y.G., Darskaya E.I., Kozlov A.V., Bikova T.A., Zubarovskaya L.S., Afanasyev B.V. |
| 38 | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2018;11(1):3-18. DOI: 10.17749/2070-4909.2018.11.1.003-018 | Vilyum I.A., Andreev B.V., Proskurin M.A., Balykina Y.E. |
| 39 | Clinical and economic analysis of the use of antipsychotic drugs in hospital for the treatment of schizophrenia | Clinical pharmacology and therapy. 2018;27(2):69-76. | Vilyum I.A., Andreev B.V., Balykina Yu.E., Proskurin M.A. |
| 40 | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2018;11(2):9-24. DOI: 10.17749/2070-4909.2018.11.2.009-024 | Vilyum I.A., Andreev B.V., Balykina Y.E., Proskurin M.A. |
| 41 | Pharmacoeconomic expediency of using the coformulated Vezomni in comparison with a combination of Tamsulosin and Solifenacin in the form of single entity tablets | Good clinical practice. 2018;(1):35-40. DOI: 10.24411/2588-0519-2018-10036 | Zyryanov S.K., Dyakov I.N. |

**II. Oral and Poster Presentations on Pharmacoeconomics and Health Technology Assessment at the ISPOR International and European Meetings**

|  |  |  |  |
| --- | --- | --- | --- |
| № | Conference Title | Report Title | Venue |
| 1 | ISPOR 21th Annual European Congress | Pharmacoeconomic Study of the Effectiveness and Safety of Antipsychotics | November 10-14, 2018, Barcelona, Spain |
| 2 | ISPOR 21th Annual European Congress | Influence of the Time Horizon Length on the Results of Pharmacoeconomic Research | November 10-14, 2018, Barcelona, Spain |
| 3 | ISPOR 21th Annual European Congress | The Use of Obinutuzumab in Treatment of Refractory and Relapsing Follicular Lymphoma | November 10-14, 2018, Barcelona, Spain |
| 4 | ISPOR 21th Annual European Congress | Health-Economic Evaluation of Pharmacogenetic Tests in Psychiatric In-Patient Care | November 10-14, 2018, Barcelona, Spain |
| 5 | ISPOR 2018 | Estimated Budget Impact of Cholesterol Decreasing in the Russian Population | May 19–23, Baltimore, USA |
| 6 | ISPOR 2018 | Social and Economic Impact of Diabetes Mellitus Type 2 and it’s Cardiovascular Complications on the Workforce in the Russian Federation | May 19–23, Baltimore, USA |
| 7 | ISPOR 21th Annual European Congress | Pharmacoeconomic Evaluation of Pharmacological Treatment Options for Patients with Moderately-Severe and Severe Psoriasis and Resistance to the Base Therapy | November 10-14, 2018, Barcelona, Spain |
| 8 | ISPOR 21th Annual European Congress | Pharmacoeconomic Analysis of Drug Therapy of Chronic Heart Failure in Patients with Comorbid Conditions | November 10-14, 2018, Barcelona, Spain |
| 9 | ISPOR 21th Annual European Congress | Economic Assessment of Effectiveness and Safety of Common Practice Perioperative Antibiotic Prophylaxis in a Multidisciplinary Hospital | November 10-14, 2018, Barcelona, Spain |
| 10 | ISPOR 21th Annual European Congress | The Structure of Consumption of Antimicrobial Drug for Systemic Use in Multidisciplinary Hospitals in St. Petersburg in 2014-2015 | November 10-14, 2018, Barcelona, Spain |
| 11 | ISPOR 21th Annual European Congress | Pharmacoeconomic Modes of Antibiotic Therapy of Uncomplicated Community-Acquired Acute Pyelonephritis in a Multidisciplinary Hospitals | November 10-14, 2018, Barcelona, Spain |
| 12 | ISPOR Asia Pacific 2018. Value-based decision making in developing countries: multi-criteria decision analysis (MCDA) for off-patent pharmaceuticals | Multicriteria Decision Analysis in Russia | September 8-11, 2018, Tokyo, Japan |
| 13 | ISPOR 21th Annual European Congress | Pharmacoeconomic Analysis of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | November 10-14, 2018, Barcelona, Spain |
| 14 | ISPOR 21th Annual European Congress | Pharmacoeconomics of Different Treatments for Steroid-Refractory Graft Versus Host Disease: Analysis of Treatment Results in a Single-Center Study | November 10-14, 2018, Barcelona, Spain |

**III. Reports in the Field of Pharmacoeconomics and Health Technology Assessment at Russian and International Conferences**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № | Conference Title | Report Title | Dates | Venue |
| 1 | Challenges in endocrinology, Republican Conference (Republic of Dagestan) | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | November 9, 2018 | Makhachkala |
| 2 | Effective Methods for the Diagnosis and Control of Diabetes | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | November 27, 2018 | Omsk |
| 3 | Prevention of Complications in Patients with Type 2 Diabetes | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | December 14, 2018 | Veliky Novgorod |
| 4 | Epidemiology and Economic Burden of Diabetes Mellitus | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | December 12, 2018 | Petrozavodsk |
| 5 | Current Problems in Diabetes Treatment | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | June 29, 2018 | Astrakhan |
| 6 | Economic Burden of Diabetes Mellitus | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | September 28, 2018 | Ulan-Ude |
| 7 | Issues of Drug Support for Patients with Diabetes Mellitus | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | August 29, 2018 | Vladimir |
| 8 | Modern Approaches in the Treatment of Diabetes | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | October 10, 2018 | Ryazan |
| 9 | Pharmaceutical Section of the Regional Conference for Healthcare Professionals | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | March 30, 2018 | Murmansk |
| 10 | II Interregional Scientific and Practical Conference “Diabetes and other aspects of modern endocrinology” | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | April 12, 2018 | Nizhny Novgorod |
| 11 | Regional Conference Dedicated to the 50th Anniversary of the Medical University | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | June 23, 2018 | Penza |
| 12 | District Scientific Practical Conference “Achievements and prospects of clinical endocrinology in the practice of specialists in allied health specialties” | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | October 26, 2018 | Surgut |
| 13 | Round Table on Effective Treatment of Diabetes Mellitus | Clinical and Economic Aspects of Effective Control of Type 2 Diabetes Mellitus and its Complications | August 23, 2018 | Tyumen |
| 14 | XIII International congress “Cardiostim 2018” | Pharmacoeconomics in Cardiology: The Economic Burden of Atrial Fibrillation | February 15, 2018 | St. Petersburg |
| 15 | Innovative Drugs in Pulmonology | Pharmacoeconomic Evaluation of Pirfenidone versus Nintedanib in Patients with Idiopathic Pulmonary Fibrosis | February 21, 2018 | St. Petersburg |
| 16 | “Rational Pharmacotherapy in the Physician Practice” with a symposium "Diseases of the Respiratory System" | From Global to Economic Burden of Disease – Evidence from the Atrial Fibrillation | February 28, 2018 | St. Petersburg |
| 17 | XII National Congress with International Participation “Development of Pharmacoeconomics and Pharmacoepidemiology in the Russian Federation” – “Pharmacoeconomics 2018” | Pharmacoeconomics of antibacterial drugs, with due regard to bacterial resistance | March 26, 2018 | Tyumen |
| 18 | All-Russian meeting “Current Issues of Clinical Pharmacology and Drug Supply” | Calculation of the Burden of Disease – the Case of Atrial Fibrillation | May 17, 2018 | Yaroslavl |
| 19 | St. Petersburg International Economic Forum | Drug provision of the population in the Russian Federation: what should be done? | May 26, 2018 | St. Petersburg |
| 20 | 3rd Regional Scientific Practical Conference with International Participation “Epidemiology of Socially Important Infections and Comorbid Conditions in North-West Europe” | Integral assessments of the quality of life in comorbid conditions against HIV infection | June 4, 2018 | St. Petersburg |
| 21 | IV St. Petersburg International Oncology Forum | The importance of drug safety in the health technology assessment | July 8, 2018 | St. Petersburg |
| 22 | Round table: “Organizational and legal aspects of assisting patients with the first psychotic episode” | Clinical and economic efficiency of modern antipsychotics | July 4, 2018 | Moscow, the Civic Chamber |
| 23 | All-Russian meeting and international scientific conference “Current issues of clinical pharmacology and drug supply” | Clinical and economic aspects of the use of biological therapy in the treatment of psoriasis and psoriatic arthritis  The system of reimbursement for patients with COPD. Pharmacoeconomic aspects | May 16, 2018 | Yaroslavl, Ministry of Health of the Russian Federation |
| 24 | XVIII All-Russian Congress of Dermatovenerologists and Cosmetologists | The choice of therapy: at the intersection of clinical data and economic approaches | May 15, 2018 | Moscow |
| 25 | The 4th annual Moscow City Conference dedicated to topical issues of clinical pharmacology “Votchalovskie readings” | Special aspects of CHF clinical pharmacology | June 1, 2018 | Moscow |
| 26 | IV Interdepartmental Conference “Financing of the Healthcare System: Problems and Solutions” | Modern immunotherapy in oncology – a breakthrough in cancer treatment, or unreasonable expenses? | December 18, 2018 | Moscow |
| 27 | I Moscow City Congress of Anesthesiology and Resuscitation “Interdisciplinary approach in anesthesiology and resuscitation” | Pharmacoeconomics of NIV: just an expensive innovation or a necessary one? | April 26, 2018 | Moscow |
| 28 | Scientific-practical conference “Innovative drugs in oncology and oncohematology” | Pharmacoeconomic assessment of innovative treatment regimens in oncology using the example of melanoma | April 19, 2018 | St. Petersburg |
| 29 | IV St. Petersburg International Oncology Forum "White Nights 2018" | Modern immuno-oncology: are the costs rational? | July 5, 2018 | St. Petersburg |
| 30 | IX All-Russian Scientific Conference with International Participation “A Strategy for Reducing Mortality from Cancer” | Pharmacoeconomic justification for the use of targeted drugs in modern oncology | October 10, 2018 | Kazan |
| 31 | Conference on psoriasis “Clean skin – deep confidence” | Therapy goal: making a choice based on economic feasibility | October 24, 2018 | St. Petersburg |
| 32 | XIII International Scientific Congress “Rational Pharmacotherapy” | Economic feasibility of innovation in oncology | October 11, 2018 | St. Petersburg |
| 33 | VI All-Russian Conference “Actual issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices” | Pharmacoeconomics of bacterial resistance based on the prediction of its development | April 19, 2018 | St. Petersburg |
| 34 | Saint Petersburg Septic Forum-2018 | Burden of resistant infections in the Russian Federation | September 12, 2018 | St. Petersburg |
| 35 | IV St. Petersburg International Oncology Forum “White Nights”, section “Pharmacoeconomics in Oncology” | Accelerated health technology assessment (mini-HTA: methodology and prospects for the use in a medical institution) | July 8, 2018 | St. Petersburg |
| 36 | ХХХХ Concluding Scientific-Practical Conference “Current issues of infectious diseases in children” | Evaluating the cost-effectiveness of chronic hepatitis C therapy | March 13, 2018 | St. Petersburg |
| 37 | Annual All-Russian Scientific Conference with International participation “New technologies in the diagnosis, treatment and prevention of HAI, infections, and parasitosis | Benefits of using 4-valent flu vaccines in health care practice | April 12, 2018 | Tyumen |
| 38 | IV St. Petersburg International Oncology Forum “White Nights 2018” | Pharmacoeconomic indicators in oncology: Procrustean bed or guiding star? | July 6-8, 2018 | St. Petersburg |
| 39 | Round table of the Civic Chamber of the Russian Federation “Vaccination of patients at risk against pneumococcal infection in the Russian Federation” | Pharmacoeconomic aspects of vaccination of patients at risk against pneumococcal infection | September 25, 2018 | Moscow |
| 40 | XIII International Scientific Congress “Rational Pharmacotherapy” | Pharmacoeconomic aspects of the prevention of human papillomavirus infection | October 11-13, 2018 | St. Petersburg |
| 41 | IV Russian Scientific Conference “Actual problems of meningococcal infection and purulent bacterial meningitis” | Pharmacoeconomic aspects of vaccination against pneumococcal infection | November 14-15, 2018 | Moscow |
| 42 | Board of Experts “Approaches to the HPV-associated cancer control: a place of vaccination in the National Strategy for the fight against cancer in the Russian Federation." | Pharmacoeconomic aspects of vaccination against human papillomavirus infection | November 16, 2018 | Moscow |
| 43 | All-Russian Congress “Immunobiological shield of Russia” | Vaccination against pneumococcal infection: pharmacoeconomic aspects | December 5, 2018 | Moscow |
| 44 | Expert Council on Psoriatic Arthritis. Evaluation of modern biological products in rheumatology | Aspects of the innovative medical technologies evaluation | February 16, 2018 | Moscow |
| 45 | Expert Council on Severe Bronchial Asthma. Evaluation of modern biological drugs in pulmonology | Basic requirements and principles for the design of pharmacoeconomic studies | July 5, 2018 | Moscow |
| 46 | Interregional round table “Preterm Newborns”, held by the Public Organization “Russian Association of Specialists in Perinatal Medicine” | Pharmacoeconomic aspects of the prevention of HRSV infection in preterm newborns | November 27, 2018 | Moscow |
| 47 | Scientific Conference “New Technologies in Oncology” | Pharmacoeconomic analysis of the use of BRAF inhibitors for the treatment of metastatic melanoma with a mutation in BRAF600 gene | April 19, 2018 | Voronezh |
| 48 | Scientific Conference with International Participation “Current issues of early diagnosis and treatment of skin tumors” | Pharmacoeconomic rationale for the selection of first-line treatment of metastatic melanoma | May 15, 2018 | St. Petersburg |
| 49 | XIII International Scientific Congress “Rational Pharmacotherapy” | Pharmacoeconomic justification for the use of TPO receptor agonists in ITP | October 11, 2018 | St. Petersburg |
| 50 | XXI Russian Oncology Congress | Efficiency at an economically reasonable price | November 14, 2018 | Moscow |
| 51 | All-Russian Meeting and International Scientific Conference “Current issues of clinical pharmacology and drug supply” | Comprehensive clinical and economic assessment of the use of obinutuzumab for lymphoproliferative diseases | May 16, 2018 | Yaroslavl |
| 52 | All-Russian Meeting and International Scientific Conference “Current issues of clinical pharmacology and drug supply” | Reference indicators in pharmacoeconomics | May 17, 2018 | Yaroslavl |
| 53 | All-Russian Meeting and International Scientific Conference “Current issues of clinical pharmacology and drug supply” | Primary specialized accreditation and professional standard. Readiness of residency graduates for real-life clinical practice | May 16, 2018 | Yaroslavl |
| 54 | All-Russian Meeting and International Scientific Conference “Current issues of clinical pharmacology and drug supply” | Meta-analysis and network meta-analysis of survival curves on the example of anticancer drugs | May 17, 2018 | Yaroslavl |
| 55 | All-Russian Meeting and International Scientific Conference “Current issues of clinical pharmacology and drug supply” | Pharmacoeconomic assessment of the use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis | May 16, 2018 | Yaroslavl |
| 56 | All-Russian Meeting and International Scientific Conference “Current issues of clinical pharmacology and drug supply” | Pharmacoeconomic analysis of the use of targeted therapy for the treatment of HER2+ breast cancer | May 16, 2018 | Yaroslavl |
| 57 | All-Russian Meeting and International Scientific Conference “Current issues of clinical pharmacology and drug supply” | The value of inhalation device in the treatment of COPD | May 16, 2018 | Yaroslavl |
| 58 | All-Russian Meeting and International Scientific Conference “Current issues of clinical pharmacology and drug supply” | Pharmacoeconomic evaluation of double bronchodilation therapy in patients with COPD | May 16, 2018 | Yaroslavl |
| 59 | VI All-Russian Conference “Actual issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices” | The choice of modeling horizon as a way to influence results in the pharmacoeconomic study. Reference Modeling Horizon | April 19, 2018 | St. Petersburg |
| 60 | VI All-Russian Conference “Actual issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices” | Methods of statistical analysis of antibacterial load in children | April 19, 2018 | St. Petersburg |
| 61 | VI All-Russian Conference “Actual issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices” | Pharmacoeconomics of bacterial resistance based on mathematical prediction of the dynamics of its development | April 19, 2018 | St. Petersburg |
| 62 | VI All-Russian Conference “Actual issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices” | Meta-analysis and network meta-analysis of survival curves, using the example of anticancer drugs | April 19, 2018 | St. Petersburg |
| 63 | IV St. Petersburg International Oncology Forum | The choice of modeling horizon as a way to influence results in the pharmacoeconomic study. Reference Modeling Horizon | July 8, 2018 | St. Petersburg |
| 64 | IV St. Petersburg International Oncology Forum | Meta-analysis and network meta-analysis of survival curves, using the example of anticancer drugs | July 8, 2018 | St. Petersburg |
| 65 | XIII International Scientific Congress “Rational Pharmacotherapy” | Pharmacoeconomic modeling as a mini-HTA tool using the example of a psychiatric hospital | October 12, 2018 | St. Petersburg |
| 66 | XIII International Scientific Congress "Rational Pharmacotherapy" | The role and place of the clinical pharmacologist in the medicine of critical conditions | October 11, 2018 | St. Petersburg |

**IV. ISPOR Chapter Journal**

Good Clinical Practice. www.clinvest.ru

**V. Branch Interaction with Authorities**

1. Participation in the Working Group on Monitoring Law Enforcement Practices of the Rules for the Compiling Restrictive Drug Lists of the Russian Federation Ministry of Health
2. Development of separate sections and editing of the document “On Approval of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030”.
3. Working as experts for two Expert Organizations under the Ministry of Health of the Russian Federation in the formalized system of the Rules for the lists of drug formation: St. Petersburg State Medical University named after acad. I.P. Pavlov; North-West State Medical University named after I.I. Mechnikov

**VI. Chapter Interaction with Professional Organizations**

1. Participation in the work of the All-Russian Association of Clinical Pharmacologists
2. Participation in the work of the Educational Methodical Committee on Clinical Pharmacology under the Ministry of Health of the Russian Federation
3. Participation in the ISPOR – CEE HTA Training and Education Project

**VII. Chapter Websites**

* <http://www.labclinpharm.ru>
* <http://www.healtheconomics.ru>
* http://hta.labclinpharm.ru
* YouTube channel: https://www.youtube.com/playlist?list=PLrajN8RdElYoRDKBcWVdhyawjsTJ8rUlQ

**VIII. Participation in International Grants and Nominations**

ISPOR Russia St. Petersburg Chapter won the “ISPOR Outstanding Regional Chapter” Award in the ISPOR Small Chapter category (10-40 Chapter members). The award ceremony was held on November 13 in Barcelona as a part of the ISPOR 21st Annual European Congress (<http://press.ispor.org/index.php/ispor-presents-annual-health-economics-and-outcomes-research-awards/>).

**IX. Educational Programs and Seminars**

1. On the base of Pavlov First Saint Petersburg State Medical University an educational course for doctors was organized and conducted, as a part of continuing medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): “Current Issues of Health Technology Assessment”, March 2018
2. On the base of Pavlov First Saint Petersburg State Medical University an educational course for doctors was organized and taught, as a part of continuing medical education (the course information is posted on the Continuing Medical and Pharmaceutical Education Portal (http://edu.rosminzdrav.ru/): “Current Issues of Health Technology Assessment”, October 2018
3. At the North-Western State Medical University named after I.I. Mechnikov, the issues of health technology assessment were introduced in the Master's programs majoring in Public Health and included in the medical residency program majoring in Healthcare Organization and Public Health.
4. At the St. Petersburg State Chemical Pharmaceutical Academy, the Pharmacoeconomic Analysis course is included in the basic part of the medical residency education program majoring in Management and Economics of Pharmacy, as well as in the educational program for students of the pharmaceutical faculty majoring in Pharmacy.

**X. Organizational Work**

1. Within the framework of the VI All-Russian conference with international participation “Current issues of preclinical and clinical studies of drugs, biomedical cell products and clinical trials of medical devices”, the “Health Technology Assessment” section was organized and held (April 20, 2018).
2. Within the framework of the IV St. Petersburg International Oncology Forum, the “Health Technology Assessment” section was held (July 8, 2018).
3. Within the framework of the St. Petersburg Septic Forum, the “Health Technology Assessment” section was held (September 12, 2018).

**XI. Chapter Plans for the Future**

1. Working on a textbook “Pharmacoeconomics and Clinical Economic Analysis”